Is uniQure NV overvalued or undervalued?

As of 8 August 2022, the valuation grade for uniQure NV has moved from fair to risky, indicating a significant deterioration in its financial outlook. The company is currently considered overvalued, especially given its troubling financial ratios. The Price to Book Value stands at 28.07, while the EV to EBITDA ratio is -6.16, reflecting negative earnings performance. Additionally, the Return on Capital Employed (ROCE) is a staggering -144.66%, and the Return on Equity (ROE) is at -666.88%, underscoring the company's struggles to generate returns.
In comparison with peers, uniQure NV's P/E ratio is -3.6045, while Precigen, Inc. has a P/E of -5.1033, and MaxCyte, Inc. stands at -5.5923, all indicating similar financial distress within the sector. The company's recent stock performance has also been underwhelming, with a year-to-date return of -21.01%, contrasting sharply with the S&P 500's 2.44% gain. This combination of poor financial metrics and relative performance suggests that uniQure NV is currently overvalued in the market.